Ubs Group Ag Stoke Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
2 transactions
Others Institutions Holding STOK
# of Institutions
125Shares Held
57.6MCall Options Held
9.3KPut Options Held
35.2K-
Skorpios Trust8.91MShares$98.1 Million99.85% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$59.6 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.19MShares$57.2 Million22.82% of portfolio
-
Redmile Group, LLC San Francisco, CA4.71MShares$51.9 Million3.79% of portfolio
-
Rtw Investments, LP New York, NY4.65MShares$51.3 Million0.91% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $434M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...